Back to Search Start Over

A matter of public interest

Authors :
Vittorio Bertele
Silvio Garattini
Source :
BMJ. 341:c3721-c3721
Publication Year :
2010
Publisher :
BMJ, 2010.

Abstract

Bevacizumab is better than no treatment, photodynamic treatment, or six weekly intravitreal pegaptanib sodium in neovascular age related macular degeneration (AMD).1 Its long term safety and whether it is as effective as ranibizumab are unknown,2 but available data should be sufficient for the European Medicine Agency (EMA) to …

Details

ISSN :
14685833 and 09598138
Volume :
341
Database :
OpenAIRE
Journal :
BMJ
Accession number :
edsair.doi...........6c230fe7815ccb8145a0dc3ab0a2615b